S&P 500   5,089.82 (+0.02%)
DOW   39,200.22 (+0.18%)
QQQ   437.29 (+0.12%)
AAPL   181.58 (-0.52%)
MSFT   409.43 (-0.22%)
META   481.98 (-0.42%)
GOOGL   140.14 (-2.65%)
AMZN   175.14 (+0.09%)
TSLA   198.66 (+3.48%)
NVDA   794.47 (+0.80%)
NIO   5.68 (+5.19%)
AMD   176.59 (+0.04%)
BABA   76.03 (+0.09%)
T   16.78 (-0.12%)
F   12.16 (+0.16%)
MU   89.82 (+4.44%)
CGC   3.52 (+4.76%)
GE   154.71 (+0.90%)
DIS   108.63 (+0.83%)
AMC   4.52 (+1.80%)
PFE   27.35 (-1.48%)
PYPL   59.30 (+0.24%)
XOM   104.71 (+0.84%)
S&P 500   5,089.82 (+0.02%)
DOW   39,200.22 (+0.18%)
QQQ   437.29 (+0.12%)
AAPL   181.58 (-0.52%)
MSFT   409.43 (-0.22%)
META   481.98 (-0.42%)
GOOGL   140.14 (-2.65%)
AMZN   175.14 (+0.09%)
TSLA   198.66 (+3.48%)
NVDA   794.47 (+0.80%)
NIO   5.68 (+5.19%)
AMD   176.59 (+0.04%)
BABA   76.03 (+0.09%)
T   16.78 (-0.12%)
F   12.16 (+0.16%)
MU   89.82 (+4.44%)
CGC   3.52 (+4.76%)
GE   154.71 (+0.90%)
DIS   108.63 (+0.83%)
AMC   4.52 (+1.80%)
PFE   27.35 (-1.48%)
PYPL   59.30 (+0.24%)
XOM   104.71 (+0.84%)
S&P 500   5,089.82 (+0.02%)
DOW   39,200.22 (+0.18%)
QQQ   437.29 (+0.12%)
AAPL   181.58 (-0.52%)
MSFT   409.43 (-0.22%)
META   481.98 (-0.42%)
GOOGL   140.14 (-2.65%)
AMZN   175.14 (+0.09%)
TSLA   198.66 (+3.48%)
NVDA   794.47 (+0.80%)
NIO   5.68 (+5.19%)
AMD   176.59 (+0.04%)
BABA   76.03 (+0.09%)
T   16.78 (-0.12%)
F   12.16 (+0.16%)
MU   89.82 (+4.44%)
CGC   3.52 (+4.76%)
GE   154.71 (+0.90%)
DIS   108.63 (+0.83%)
AMC   4.52 (+1.80%)
PFE   27.35 (-1.48%)
PYPL   59.30 (+0.24%)
XOM   104.71 (+0.84%)
S&P 500   5,089.82 (+0.02%)
DOW   39,200.22 (+0.18%)
QQQ   437.29 (+0.12%)
AAPL   181.58 (-0.52%)
MSFT   409.43 (-0.22%)
META   481.98 (-0.42%)
GOOGL   140.14 (-2.65%)
AMZN   175.14 (+0.09%)
TSLA   198.66 (+3.48%)
NVDA   794.47 (+0.80%)
NIO   5.68 (+5.19%)
AMD   176.59 (+0.04%)
BABA   76.03 (+0.09%)
T   16.78 (-0.12%)
F   12.16 (+0.16%)
MU   89.82 (+4.44%)
CGC   3.52 (+4.76%)
GE   154.71 (+0.90%)
DIS   108.63 (+0.83%)
AMC   4.52 (+1.80%)
PFE   27.35 (-1.48%)
PYPL   59.30 (+0.24%)
XOM   104.71 (+0.84%)
NASDAQ:TGTX

TG Therapeutics (TGTX) Stock Price, News & Analysis

$13.54
+0.22 (+1.65%)
(As of 10:16 AM ET)
Today's Range
$13.23
$13.73
50-Day Range
$13.02
$21.30
52-Week Range
$6.46
$35.67
Volume
641,804 shs
Average Volume
4.86 million shs
Market Capitalization
$2.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.00

TG Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
93.7% Upside
$26.00 Price Target
Short Interest
Healthy
21.35% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.46
Upright™ Environmental Score
News Sentiment
0.51mentions of TG Therapeutics in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$1.14 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From $0.08 to ($0.10) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.79 out of 5 stars

Medical Sector

238th out of 935 stocks

Pharmaceutical Preparations Industry

107th out of 429 stocks


TGTX stock logo

About TG Therapeutics Stock (NASDAQ:TGTX)

TG Therapeutics Inc is a biopharmaceutical company that develops and commercializes innovative treatments for multiple sclerosis (MS) and other autoimmune diseases. The company, founded in 2012, is headquartered in New York City and has operations in the United States and Europe. The company aims to provide new and effective therapies to patients with unmet medical needs.

TG Therapeutics has made significant achievements since its inception but has also experienced significant setbacks. The company initially rose to fame by producing the cancer drug Ukoniq which was later pulled from the market due to its ineffectiveness. The company shifted focus and received FDA approvals for a multiple sclerosis drug, Briumvi, for relapsing forms of multiple sclerosis. Additionally, the company conducts extensive clinical trials for other product candidates. These product candidates can potentially provide new treatment options for patients with B-cell malignancies and autoimmune diseases.

TG Therapeutics has a talented and experienced management team dedicated to advancing the company's mission. The current CEO and co-founder of the company is Michael S. Weiss, who has over 25 years of experience in the biopharmaceutical industry. TG Therapeutics has seen financial growth and decline over the past few years. The company has reported significant losses primarily due to removing Ukoniq from its product line and increased investment in clinical development and research activities. 

TG Therapeutics has seen significant volatility in its stock price over the past few years. In 2021, the stock price increased by over 200% due to positive clinical trial results for its product candidates. However, in 2022, the stock price experienced a sharp decline due to concerns about removing the approved drug Ukoniq from the market, delays in clinical development and increased competition. 

TG Therapeutics operates in the biopharmaceutical industry, characterized by high innovation levels and significant regulatory oversight. The industry is also subject to political and economic pressures, including changes in healthcare policy and pricing pressures from payers.

TG Therapeutics faces competition from other companies developing cancer and autoimmune disease treatments, including large pharmaceutical companies such as Roche and Novartis. However, the company's focus on developing novel therapies for unmet medical needs gives it a competitive advantage.

TG Therapeutics has several growth opportunities in its pipeline. The company is currently developing new product candidates which have the potential to provide new treatment options for patients with MS, B-cell malignancies and autoimmune diseases. Additionally, the company may pursue strategic acquisitions or partnerships to expand its product portfolio and reach new markets.

TG Therapeutics faces risks and challenges that may impact its future growth and success. These include changes in healthcare policy and pricing pressures from payers and increased competition from other companies in the market. Additionally, the company is subject to regulatory oversight and must successfully navigate the clinical development and approval process for its product candidates. Failure to do so may result in delays, increased costs, and potential setbacks for the company.

The company's financial performance is also subject to risks, such as changes in interest rates and the availability of financing. The company's debt levels may limit its ability to invest in research and development. Any significant changes in ownership or management may also disrupt operations and impact the company's growth potential.

Furthermore, the success of TG Therapeutics' product candidates is not guaranteed, and the company may need help demonstrating their safety and efficacy in clinical trials. Failure to obtain regulatory approval for these products or to effectively commercialize them may significantly impact the company's financial performance and market position.

TGTX Stock Price History

TGTX Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
TG Therapeutics (NASDAQ:TGTX) Stock Rating Lowered by StockNews.com
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
StockNews.com Upgrades TG Therapeutics (NASDAQ:TGTX) to Buy
TG Therapeutics Inc
TG Therapeutics price target raised by $5 at B. Riley, here's why
TGTX Feb 2024 21.500 call
TG Therapeutics price target lowered by $1 at JPMorgan, here's why
TGTX Feb 2024 21.000 call
Ardelyx's XPHOZAH Still An Afterthought To The Pros
TG Therapeutics Targets Briumvi U.S. Product Revenue Of $40 Mln In Q4
Goldman Sachs Sticks to Their Hold Rating for TG Therapeutics (TGTX)
See More Headlines
Receive TGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
2/26/2024
Next Earnings (Estimated)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TGTX
Employees
245
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$26.00
High Stock Price Target
$45.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+95.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-198,340,000.00
Pretax Margin
-13.65%

Debt

Sales & Book Value

Annual Sales
$2.79 million
Book Value
$0.40 per share

Miscellaneous

Free Float
137,480,000
Market Cap
$2.02 billion
Optionable
Optionable
Beta
2.42
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report














TGTX Stock Analysis - Frequently Asked Questions

Should I buy or sell TG Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TGTX shares.
View TGTX analyst ratings
or view top-rated stocks.

What is TG Therapeutics' stock price target for 2024?

6 Wall Street research analysts have issued 1 year price objectives for TG Therapeutics' stock. Their TGTX share price targets range from $12.00 to $45.00. On average, they predict the company's share price to reach $26.00 in the next year. This suggests a possible upside of 93.7% from the stock's current price.
View analysts price targets for TGTX
or view top-rated stocks among Wall Street analysts.

How have TGTX shares performed in 2024?

TG Therapeutics' stock was trading at $17.08 at the beginning of 2024. Since then, TGTX stock has decreased by 21.4% and is now trading at $13.42.
View the best growth stocks for 2024 here
.

When is TG Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our TGTX earnings forecast
.

How were TG Therapeutics' earnings last quarter?

TG Therapeutics, Inc. (NASDAQ:TGTX) announced its quarterly earnings results on Wednesday, November, 1st. The biopharmaceutical company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.29 by $0.44. The biopharmaceutical company earned $165.80 million during the quarter, compared to analyst estimates of $23.91 million. TG Therapeutics had a negative net margin of 13.65% and a negative trailing twelve-month return on equity of 35.58%. The company's quarterly revenue was up 17538.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.26) earnings per share.

What ETFs hold TG Therapeutics' stock?

ETFs with the largest weight of TG Therapeutics (NASDAQ:TGTX) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE).AdvisorShares Let Bob AI Powered Momentum ETF (LETB).

What other stocks do shareholders of TG Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TG Therapeutics investors own include Novavax (NVAX), AK Steel (AKS), Micron Technology (MU), Cara Therapeutics (CARA), Gilead Sciences (GILD), UrtheCast (UR), Verastem (VSTM), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE) and Corbus Pharmaceuticals (CRBP).

Who are TG Therapeutics' major shareholders?

TG Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.03%), Opaleye Management Inc. (1.46%), Goldman Sachs Group Inc. (1.09%), Northern Trust Corp (0.89%), Nuveen Asset Management LLC (0.89%) and Charles Schwab Investment Management Inc. (0.75%). Insiders that own company stock include Laurence N Charney, Michael S Weiss, Sagar Lonial, Sean A Power and Yann Echelard.
View institutional ownership trends
.

How do I buy shares of TG Therapeutics?

Shares of TGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TGTX) was last updated on 2/26/2024 by MarketBeat.com Staff